Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

KSHN001126

Small molecule · developed by Amneal Pharmaceuticals, LLC

Phase 1 Most advanced trial (none active)

AMRX Developer

1 Registered trials

What is KSHN001126?

KSHN001126 is an orally administered agent studied at single oral doses of 150 mg, 300 mg and 600 mg in healthy postmenopausal women.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Women's health
Developer: Amneal Pharmaceuticals, LLC (AMRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06467201	Phase 1	Healthy Postmenopausal Women	Completed	AMRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Postmenopausal Women

More from Amneal Pharmaceuticals, LLC

Test Product Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AMRX page.

Follow AMRX, the company behind KSHN001126

See AMRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z